Dihydroartemisinin-piperaquine or sulphadoxine-pyrimethamine for the chemoprevention of malaria in children with sickle cell anaemia in eastern and southern Africa (CHEMCHA): a protocol for a multi-centre, two-arm, double-blind, randomised, placebo-controlled superiority trial

Thandile Nkosi-Gondwe, Bjarne Robberstad, Robert Opoka, Dennis Kalibbala, Joseph Rujumba, Lufina Tsirizani Galileya, Pamela Akun, Winnie Nambatya, John Ssenkusu, Feiko TerKuile, Kamija Phiri, Richard Idro

Research output: Contribution to journalArticlepeer-review

Abstract

Background: An estimated 300,000 babies are born with sickle cell anaemia (SCA) annually. Affected children have chronic ill health and suffer premature death. Febrile illnesses such as malaria commonly precipitate acute crises in children with SCA. Thus, chemoprophylaxis for malaria is an important preventive strategy, but current regimes are either sub-optimally effective (e.g. monthly sulphadoxine-pyrimethamine, SP) or difficult to adhere to (e.g. daily proguanil). We propose dihydroartemisinin-piperaquine (DP) as the agent with the most potential to be used across Africa. Methods: This will be a randomised, double-blind, parallel-group superiority trial of weekly single-day courses of DP compared to monthly single-day courses of SP in children with SCA. The study will be conducted in eastern (Uganda) and southern (Malawi) Africa using randomisation stratified by body weight and study centre. Participants will be randomised using an allocation of 1:1 to DP or SP. We will investigate the efficacy, safety, acceptability and uptake and cost-effectiveness of malaria chemoprevention with weekly courses of DP vs monthly SP in 548 to 824 children with SCA followed up for 12–18 months. We will also assess toxicity from cumulative DP dosing and the development of resistance. Participant recruitment commenced on 30 April 2021; follow-up is ongoing. Discussion: At the end of this study, findings will be used to inform regional health policy. This manuscript is prepared from protocol version 2.1 dated 1 January 2022. Trial registration: The trial was registered at ClinicalTrials.gov, NCT04844099. Registered on 08 April 2021.

Original languageEnglish
Article number257
JournalTrials
Volume24
Issue number1
DOIs
Publication statusPublished - Dec 2023

Keywords

  • Chemoprevention
  • Dihydroartemisinin-piperaquine
  • Malaria
  • Mortality
  • Sickle cell anaemia
  • Sulphadoxine-pyrimethamine

Fingerprint

Dive into the research topics of 'Dihydroartemisinin-piperaquine or sulphadoxine-pyrimethamine for the chemoprevention of malaria in children with sickle cell anaemia in eastern and southern Africa (CHEMCHA): a protocol for a multi-centre, two-arm, double-blind, randomised, placebo-controlled superiority trial'. Together they form a unique fingerprint.

Cite this